All In Biotech

Drug Trial Radar · NCT06517914

A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants

A First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Oral Administration of YH35995 in Healthy Adult Male Participants

Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

94

Actual

Start

Jul 29, 2024

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Yuhan CorporationIndustry
Sponsor type
Industry
First posted
Jul 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 19 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, first-in-human study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of YH35995

Conditions

  • Healthy Participants

Interventions

  • YH35995Drug

    Oral administration of YH35995

  • PlaceboDrug

    Oral administration of Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Part A, B] Treatment-emergent adverse events (TEAEs)Time frame: Part A: Day1-150, Part B: Day1-232

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHA Bundang Medical Center

    Seongnam, Bundang-gu, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.